f-chemotactic peptide has been researched along with propofol in 1 studies
| Studies (f-chemotactic peptide) | Trials (f-chemotactic peptide) | Recent Studies (post-2010) (f-chemotactic peptide) | Studies (propofol) | Trials (propofol) | Recent Studies (post-2010) (propofol) |
|---|---|---|---|---|---|
| 79 | 0 | 4 | 16,827 | 5,188 | 6,805 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, SH; Chen, CY; Huang, WJ; Hwang, TL; Tsai, YF | 1 |
1 other study(ies) available for f-chemotactic peptide and propofol
| Article | Year |
|---|---|
Propofol inhibits endogenous formyl peptide-induced neutrophil activation and alleviates lung injury.
Topics: Acute Lung Injury; Animals; Cell Movement; Chemotactic Factors; Gene Expression Regulation; Humans; L-Lactate Dehydrogenase; Leukocyte Elastase; Lipopolysaccharides; Lung; Male; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; Neutrophil Activation; Neutrophils; Oligopeptides; Peroxidase; Primary Cell Culture; Propofol; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Receptors, Formyl Peptide; Sepsis; Signal Transduction; Survival Analysis | 2018 |